Caricamento...
Disease‐Modifying Treatments for Progressive Supranuclear Palsy
In recent years, research has focused on the development of disease‐modifying treatments for PSP, targeting mainly at tau dysfunction. However, the glycogen synthase kinase 3 inhibitor, tideglusib, and the microtubuli stabilizer, davunetide, both failed to show efficacy in recent double‐blind, place...
Salvato in:
| Pubblicato in: | Mov Disord Clin Pract |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6183250/ https://ncbi.nlm.nih.gov/pubmed/30363906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12142 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|